InvestSMART

Archer Materials Limited (ASX:AXE)

ALERT: Price-sensitive ASX Announcement for AXE
Current share price for AXE : $0.180 -0.035 (-16.28%)+
Announcement
Release
29 Jul 2026 9:32AM
Price at Release
$0.215
Full Release
download
Summary
Archer Materials Limited (ASX: AXE) has made significant progress towards the development of a clinical-ready Biochip device aimed at potassium testing. The company has integrated haemolysis sensing technology with its Biochip platform to detect plasma free haemoglobin which can distort potassium readings, achieving sensitivity suitable for clinical settings. Additionally, Archer is expanding its Biochip platform capabilities to include lithium testing, demonstrating high accuracy suitable for therapeutic monitoring of lithium-based drugs. This advancement supports the preparation for a pre-submission meeting with the FDA, indicating a step towards regulatory readiness. Archer is focused on ensuring the manufacturability and usability of its Biosensor device in clinical workflows, aligning with its goal of establishing a scalable, reliable, and easy-to-use system that benefits healthcare providers and patients.
Key Points
  • Industrial design for clinically deployable potassium testing device commenced.
  • Integration of haemolysis sensing with Biochip platform completed.
  • Biochip platform expanded for lithium testing with high accuracy.
  • Progress supports pre-submission meeting with the FDA.
  • Focus on manufacturability and usability in clinical settings.
  • Partnership discussions for lithium tester device development ongoing.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.